If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
UROLOGY
ISSN 2053-4213 May 2014 • emjreviews.com
INSIDE
Review of
EAU 2014
Stockholm, Sweden
CONTENTS
EDITORIAL BOARD................................................................................................................................. 4
CONGRESS REVIEW............................................................................................................................... 8
• Review of the European Association of Urology Congress held in Stockholm,
Sweden, 11th-15th April 2014
SYMPOSIUM REVIEWS
• The Many Faces Of mCRPC: Assessing Patient Profiles And Tailoring Treatment In
A Changing Therapeutic Landscape.............................................................................................. 28
• Innovative Approaches In Urologi
UROLOGY ISSN 2053-4213
CONTENTS EDITORIAL BOARD.......................
UROLOGY ATHEROSCLEROSIS AND INFLAMMATORY STATU
Editorial Board Urology Editor-in-Chief: Dr Al
Welcome Welcome to the second edition of the Euro
European Medical Journal Urology May 2014 Publ
Foreword Dr Ali Serdar Gözen
EAU ANNUAL CONGRESS 2014 STOCKHOLMSMÄSSAN, STOCKH
Welcome to the European Medical Journal review of
EAU ANNUAL CONGRESS 2014 STOCKHOLMSMÄSSAN, STOCKH
At the opening ceremony, the EAU Congress r
EAU ANNUAL CONGRESS 2014 STOCKHOLMSMÄSSAN, STOCKH
Pelvic floor muscle exercises: the solution to pre
EAU ANNUAL CONGRESS 2014 STOCKHOLMSMÄSSAN, STOCKH
A giant leap forward for robotic surgery A FRONTI
EAU ANNUAL CONGRESS 2014 STOCKHOLMSMÄSSAN, STOCKH
Nightmare of nocturia hits patient activity level
EAU ANNUAL CONGRESS 2014 STOCKHOLMSMÄSSAN, STOCKH
Golden rubric of renal transplantation ruling out
EAU ANNUAL CONGRESS 2014 STOCKHOLMSMÄSSAN, STOCKH
Non-attendance for prostate cancer monitoring cas
EAU ANNUAL CONGRESS 2014 STOCKHOLMSMÄSSAN, STOCKH
Urological tumour treatment looks to transplant t
EAU ANNUAL CONGRESS 2014 STOCKHOLMSMÄSSAN, STOCKH
Robotic technology in paediatric urology: who is
EAU ANNUAL CONGRESS 2014 STOCKHOLMSMÄSSAN, STOCKH
Three good reasons to use an antagonist in adv
THE MANY FACES OF MCRPC: ASSESSING PATIENT
demonstrated improved long-term survival when giv
Examining Biomarkers in the Management
Professor Loidl continued with the presentat
REFERENCES 1. Saad F, Hotte SJ. Guidelines for t
INNOVATIVE APPROACHES IN UROLOGICAL CANCERS Summa
other delicate surface structures to identify are
100Radiographic Progression-free Survival 80 H
cell-intrinsic phenomena. The biological capabili
the tumour, as the cytokines it releases lead to
Concluding Remarks Professor Hendrik Van Poppel
Urol. 2011;185:787–94. 31. Fizazi K et al. Abirat
GLYCOSAMINOGLYCAN-REPLENISHMENT THERAPY: RATIO
as the cellular membrane at the apical surface is
A damaged GAG layer (Figure 1) is increasingly pe
Table 1: Retrospective case-control study of effe
GAG replenishment, as well as a decrease in UTI r
useful, especially in patients who are refractory
and function of chondroitin sulfate and other sul
PROSTATE CANCER: A STATE OF THE HEART Summary of
hormones, also known as the back door pathway, al
men treated with CAB (LHRH agonist + anti-
cancer. A cohort study of 30,721 patients
As a cardiologist, Prof Nilsson concluded t
factors and the decline in mortality from cardiov
HEALTH AND WELLBEING IMPACT AND TREATMENT OF
population studies. Using the clinically rel
impacting on QoL. The Boston Area Community Healt
LUTS/BPH Pharmacotherapy Alpha-blockers are the m
REFERENCES 1. Abrams P et al. The standardisatio
48. Cardozo L et al. Randomized, double- blind pl
INCREASED HYALURONAN ACID BINDING ABILITY OF S
autoimmunity. In about 50% of all sub-/infertile
Primary Outcome Assessment: SHBA Values The prese
higher than the 2.1% decrease observed in
of sperm DNA integrity. An increase of hyaluronan
21. Suleiman SA et al. Lipid peroxidation and hum
PREVENTION OF CATHETER-ASSOCIATED URINARY TRACT
Significant bacteriuria or positive urine culture
dose of chemoprophylaxis; 8) duration of post- ca
to surgery, and ending anywhere from catheter rem
Table 1: Rating of randomised controlled trials
In the only study comparing methenamine with an a
that although prophylaxis is not without si
6. Pickard R et al. Types of urethral catheter fo
ATHEROSCLEROSIS AND INFLAMMATORY STATUS IN CHRO
Besides traditional risk factors incl
CV outcomes and why these anticipated e
A.51,52 ABPM may be more informative regarding th
Vessels In health
calcification (MIAC) syndrome. MIAC syndrome has b
4.3%, 5.2%, and 11.1%, respectively. The principa
American Heart Association Task Force on Practi
of RAW264.7 cells in the absence of Fn14/Tw
RECENT ADVANCES IN PERCUTANEOUS NEPHROLITHOTOMY *
IMAGING Computed tomography (CT) is
The ROC AUC for predictions based on this
Nine patients were stone-free at the end o
The use of augmented reality
needed. The most important advancement in
prostate cancer: demonstration of an adaptive
A LITERATURE-BASED ANALYSIS OF THE LE
Coinciding with a similar rise in the rate of RAR
Outcome variable (e.g. PSM) Plateau area of curv
Table 1: Studies evaluating the perioperative lea
The oncologic LC consists of two variables: the P
authors were unable to demonstrate a plateauing o
measure it and can we influence it? BJU Int. 2004;
LAPAROSCOPIC RADICAL PROSTATECTOMY IN THE
Table 1: Perioperative outcomes of laparoscopic r
compared with open prostatectomy. A recent a
Table 2: Oncological outcomes of laparoscopic rad
25 (27%) met the pentafecta. The majority (80%) o
is expected to be reduced and its worldwid
extraperitoneal radical prostatectomy: evolut
ROBOTIC RADICAL CYSTECTOMY FOR BLADDER
(1A)
Consortium (IRCC) series, a PSM rate
the edge of the endopelvic fascia over the
surgery, following the insertion of ureteral sten
hospital stay, and time to resumption of regular
cancer’. Canda AE (eds), Bladder Cancer: From Bas
NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE
However, until today, optimal timing of the thera
Cystectomy Trial I, and the second, N
WHO SHOULD RECEIVE NAC? As discussed above, MIBC
However, the study was retrospective in nature, a
been previously used in metastatic melanoma and
cancer results in worse pathological stage. J
WHAT’S NEW Personalising said Mr Roman Gulati, le
UROLOGY One drug to cure two cancers TRASTUZUMAB
WHAT’S NEW Dance incontinence away DANCING is not
UROLOGY Increased testosterone leading to increas
WHAT’S NEW Prostate cancer drugs not preventing r
UROLOGY ADT: changing men, both mentally and emot
WHAT’S NEW Botox: combatting wrinkles and incont
Would you like to write for the EMJ blog? Intera
Featured Suppliers Urology Responsible for th
From a host of fifteen therapeutic areas, EUROPEAN
Buyer’s Guide Exhibitors • A.M.I. GMBH • AESCU
• KOELIS • LABORIE • LASER PERIPHERALS • LENUS
UPCOMING EVENTS Annual Meeting of the British As
UROLOGY 32nd World Congress of Endourology 3rd-7
SUBSCRIBE TO RECEIVE THE LATEST CATIONS PUBLI